Behçet's syndrome in pregnancy

Area of Science:

• Rheumatology
• Obstetrics
• Immunology

Background:

• Behçet's syndrome (BS) is a rare systemic inflammatory disease affecting young adults.
• Characterized by oral/genital ulcers, uveitis, and arthritis, BS typically impacts the third and fourth decades of life.

Purpose of the Study:

• To review the impact of Behçet's syndrome on pregnancy outcomes.
• To assess the safety of common Behçet's syndrome treatments during pregnancy and breastfeeding.

Main Methods:

• Literature review of studies on Behçet's syndrome in pregnancy.
• Analysis of drug safety profiles for immunosuppressants and biologics used in BS management.

Main Results:

• Behçet's syndrome typically shows improvement during pregnancy, though its course can be unpredictable.
• Corticosteroids, azathioprine, calcineurin inhibitors, and colchicine are generally considered safe for use during pregnancy and breastfeeding.
• Experience with biologics in pregnancy is growing.

Conclusions:

• Behçet's syndrome generally has a favorable prognosis in pregnancy with appropriate management.
• Certain medications, including methotrexate, mycophenolate mofetil, thalidomide, cyclophosphamide, and chlorambucil, should be avoided in pregnant or planning-to-be-pregnant individuals.
• Close monitoring and individualized treatment plans are essential for managing Behçet's syndrome during pregnancy.